From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis

Figures & data

Table 1 NGS on Lung Cancer Risk Screening

Reference	Country	Published Year	No. of Participants	Participants with LC	Detection Object	Potential Biomarkers of LC
Jing Hu^Citation83	China	2019	122	122 (100.0%)	Genes	TP53, RB1, LRP1B, KMT2D, FAT1, KMT2C, SPTA1, STK24, FAM135B, NOTCH1
Ana B. Pavel^Citation84	USA	2017	347	194 (56.0%)	miRNA	miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p
Andreas Keller^Citation79	Germany	2018	534	33 (6.2%)	miRNA	miR-548d-5p, miR-4695-3p, miR-517a-3p, miR-4785, miR-7109-3p, miR-320e, miR-548ay-5p, miR-320c, miR-519d-3p
Wenhua Liang^Citation80	China	2019	230	129 (56.1%)	CTDNA methylation	9 hypermethylated markers
Zhe Su^Citation81	China	2019	48	48 (100.0%)	CTC	10-CNA score

Abbreviations: NGS, next generation sequencing; LC, lung cancer; CTC, circulating tumor cell; CTDNA, circulating tumor DNA; CNA, copy number alteration.

Table 2 Studies on COPD in the Immunotherapy of Lung Cancer

Reference	Country	Published Year	No. of Participants Treated with ICIs	Participants with COPD	Evaluation Index	Outcome Related Factors	Study Design
Nicholas M. Mark, M.D^Citation100	USA	2017	73	44(60.2%)	PFS	IFN-γ-producing CD8(+) and CD4(+)Th1 cells	Retrospective cohort study
Jérˆome Biton^Citation106	French	2018	39	19(48.7)	PFS, OS	CD8(+) TIL	Retrospective cohort study
Yuzo Suzuki^Citation101	Japan	2019	95	41(43.2%)	FeNO, FVC, FEV1	_	Prospective multi-center study
Jiebai Zhou^Citation103	China	2021	156	65(41.7%)	OS, PFS	IL-8, IL- 2R	Retrospective cohort study

Abbreviations: COPD, Chronic obstructive pulmonary disease; ICIs, immune checkpoint inhibitors; TIL, tumor infiltrates T lymphocytes; PFS, progression free survival; Os, overall survival; FeNO, fractional exhaled nitric oxide; FVC, forced vital capacity; FEV1, forced expiratory volume in the first second.

Hu J, Wang Y, Zhang Y, et al. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential. Cancer Med. 2019;8(9):4338–4347. doi:10.1002/cam4.2199

 PubMed Web of Science ®Google Scholar

Pavel AB, Campbell JD, Liu G, et al. Alterations in bronchial airway miRNA expression for lung cancer detection. Cancer Prev Res. 2017;10(11):651–659. doi:10.1158/1940-6207.Capr-17-0098

 PubMed Web of Science ®Google Scholar

Keller A, Fehlmann T, Ludwig N, et al. Genome-wide MicroRNA expression profiles in COPD: early predictors for cancer development. Genomics Proteomics Bioinformatics. 2018;16(3):162–171. doi:10.1016/j.gpb.2018.06.001

 PubMed Web of Science ®Google Scholar

Liang W, Zhao Y, Huang W, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019;9(7):2056–2070. doi:10.7150/thno.28119

 PubMed Web of Science ®Google Scholar

Su Z, Wang Z, Ni X, et al. Inferring the evolution and progression of small-cell lung cancer by single-cell sequencing of circulating tumor cells. Clin Cancer Res. 2019;25(16):5049–5060. doi:10.1158/1078-0432.Ccr-18-3571

 PubMed Web of Science ®Google Scholar

Mark NM, Kargl J, Busch SE, et al. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Am J Respir Crit Care Med. 2018;197(3):325–336. doi:10.1164/rccm.201704-0795OC

 PubMed Web of Science ®Google Scholar

Biton J, Ouakrim H, Dechartres A, et al. Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade. Am J Respir Crit Care Med. 2018;198(7):928–940. doi:10.1164/rccm.201706-1110OC

 PubMed Web of Science ®Google Scholar

Suzuki Y, Inui N, Karayama M, et al. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1867–1877. doi:10.2147/copd.S214610

 PubMed Web of Science ®Google Scholar

Zhou J, Chao Y, Yao D, et al. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. Transl Lung Cancer Res. 2021;10(5):2148–2162. doi:10.21037/tlcr-21-214

 PubMed Web of Science ®Google Scholar